A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis

Trial Profile

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Pharmacodynamics
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 01 Feb 2011 Results will be presented on 5th February at the Late Breaking Research Symposium at the annual meeting of the American Academy of Dermatology, according to a Bavarian Nordic media release.
    • 19 May 2010 Actual patient number (632) added as reported by ClinicalTrials.gov.
    • 19 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top